TIDMORPH
RNS Number : 4941O
Open Orphan PLC
10 June 2022
GENERAL TEXT AMENDMENT
The following amendment has been made to the 'BOARD APPOINTMENT'
announcement released on 8 June2022 at 07.00 under RNS No
0742O.
An amendment has been made to the past directorships /
partnerships adding Results International Group LLP
All other details remain unchanged.
The full amended text is shown below.
Open Orphan plc
("Open Orphan" or the "Company")
Board appointment
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials , announces the appointment of Martin Gouldstone as
an Independent Non-Executive Director of the Company with effect
from 8 June 2022. Martin will also Chair the Audit & Risk
Committee and will be a member of the Nominations Committee and the
Remuneration Committee.
Martin brings 30 years of corporate development experience in
the CRO, healthcare and pharmaceutical sectors, holding a number of
senior roles at healthcare AI businesses. Martin has expertise in
executing multi-billion dollar deals across Europe and the US,
architecting end-to-end portfolio out-sourcing deals, and
negotiating multi-year research partnerships.
Martin is currently Global SVP, Business Development at Owkin, a
French-American start-up using artificial intelligence to discover
and develop better treatments for unmet medical needs. Previously,
Martin has held the roles of Chief Business Officer at both
BenevolentAI and Sensyne Health and was a Partner at Results
Healthcare, an international M&A advisory firm, where he co-led
the company's healthcare practice. Prior to this, Martin was Head
of Life Sciences for BDO UK LLP, Senior Director responsible for
M&A and joint venture opportunities in Europe for Quintiles
(now IQVIA), and Business Development and Licensing Lead at
Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd.
Martin holds a BSc in Genetics and has completed a range of post
graduate management courses.
Yamin 'Mo' Khan, Chief Executive Officer of Open Orphan, said:
"I am pleased to welcome Martin to the Board of Open Orphan. Martin
has extensive corporate development experience in the CRO,
healthcare and pharmaceutical sectors and held a number of senior
roles in healthcare AI businesses. I look forward to working
closely with Martin as we drive further growth across the
business."
Martin Gouldstone, Non-Executive Director, said: "I am delighted
to join the Board of Open Orphan at what is an exciting time for
the Company and the infectious disease market as it continues to
grow significantly post pandemic. I am delighted to bring my
previous three decades of experience in the CRO, healthcare and
pharmaceutical industry to the Company as it continues to build and
expand on partnerships with leading global biopharma
companies."
Regulatory Disclosures
Save for the information set out above and below, there are no
further disclosures to be made in accordance with Rule 17, Schedule
Two (g) of the AIM Rules for Companies in respect of the
appointment of Mr Martin John Gouldstone, aged 55, Martin does not
hold an interest in the Company's share capital.
Current Directorships / Partnerships Past Directorships / Partnerships
Novara Therapeutics Limited Results International Group LLP
----------------------------------
Orthopaedic Research UK
----------------------------------
Sempiternum Ltd
----------------------------------
For further information please contact:
Open Orphan plc +44 20 7756 1300
Yamin 'Mo' Khan, Chief Executive Officer
Liberum Capital (Nominated Adviser and Joint Broker) +44 (0) 20 3100 2000
Ben Cryer / Edward Mansfield / Phil Walker / Will King
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Richard Chambers
Davy (Euronext Growth Adviser and Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Sam Allen / +44 (0)7980 541 893 / +44 (0) 7502 558 258 /
Louis Ashe-Jepson +44 (0) 7747 515393
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
contract research company that is a world leader in testing
infectious and respiratory disease products using human challenge
clinical trials. The Company provides services to Big Pharma,
biotech, and government/public health organisations.
The Company has a leading portfolio of human challenge study
models for infectious and respiratory diseases and is developing a
number of new models, such as malaria and COVID-19, to address the
dramatic growth of the global infectious disease market. The Paris
and Breda offices have over 25 years of experience providing drug
development services such as biometry, data management, statistics
CMC, PK and medical writing to third party clients as well as
supporting the London-based challenge studies.
Open Orphan runs challenge studies in London from its
Whitechapel quarantine clinic, its state-of-the-art QMB clinic with
its highly specialised on-site virology and immunology laboratory,
and its newly opened clinic in Plumbers Row. To recruit volunteers
/ patients for its studies, the Company leverages its unique
clinical trial recruitment capacity via its FluCamp volunteer
screening facilities in London and Manchester. The newly opened
facilities have expanded the scope of the business to enable the
offering of Phase I and Phase II vaccine field trials, PK studies,
bridging studies, and patient trials as part of large international
multi-centre studies.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological, and digital (wearable) biomarkers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABKKBNKBKDFAD
(END) Dow Jones Newswires
June 10, 2022 07:13 ET (11:13 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024